Cell Therapy News Volume 25.12 | Apr 08 2024

    By
    Jamie Kang
    -
    0
    7







    2024-04-08 | CTN 25.11


    Cell Therapy News by STEMCELL Technologies
    Vol. 25.09 – 8 April, 2024
    TOP STORY

    Genome Engineering with Cas9 and AAV Repair Templates Generates Frequent Concatemeric Insertions of Viral Vectors

    Scientists reported that CRISPR–Cas9 paired with adeno-associated virus serotype 6 could lead to frequent concatemeric insertions of the viral vector genome at the target site that were difficult to detect. They then described strategies to prevent the concatemeric inserts by cutting the vector genome after transduction.
    [Nature Biotechnology]

    Abstract
    Get a Head Start with Our New Lab Start-Up Program
    PUBLICATIONSRanked by the impact factor of the journal

    CD70-Targeted Allogeneic CAR T Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

    CTX130, an allogeneic CD70-targeting CAR T cell product, was developed for the treatment of advanced or refractory clear cell renal cell carcinoma (ccRCC). The authors reported that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed RCC xenograft tumors.
    [Cancer Discovery]

    Abstract

    B Cell-Directed CAR-T Cell Therapy Activates CD8+ Cytotoxic CARneg Bystander T Cells in Non-Human Primates and Patients

    Researchers performed single-cell RNA-Seq on non-human primate and patient-derived T cells to identify the phenotypic and transcriptomic hallmarks of bystander activation of CARneg T cells following B cell targeted CAR-T cell therapy.
    [Blood]

    Abstract

    Targeting Pathogenic CD8+ Tissue-Resident T Cells with Chimeric Antigen Receptor Therapy in Murine Autoimmune Cholangitis

    Treatment of Il12b-/-Il2ra-/- mice mice with PD-1-targeting CAR-T cells selectively depleted liver CD8+ memory T (Trm) cells and alleviated autoimmune cholangitis. Scientists highlighted the pathogenic role of CD8+ Trm cells and the potential therapeutic usage of PD-1-targeting CAR-T cells.
    [Nature Communications]

    Full Article

    Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer

    Researchers investigated the safety and efficacy of tumor-reactive and cytokine-activated natural killer (NK) cells, human NK cells from umbilical cord blood were expanded, transduced with a retroviral vector encoding soluble IL15, and further cytokine activated to induce PD-L1 expression.
    [Cancer Immunology Research]

    Abstract

    Class I HDAC Inhibitors Enhance Antitumor Efficacy and Persistence of CAR-T Cells by Activation of the Wnt Pathway

    Investigators identified class I histone deacetylase inhibitors (HDACi) as boosters of CAR-T cell function by high-throughput screening of chromatin-modifying drugs, in which M344 and chidamide enhance memory maintenance and resistance to exhaustion of CAR-T cells that induce sustained antitumor efficacy.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Blocking Senescence and Tolerogenic Function of Dendritic Cells Induced by γδ Treg Cells Enhances Tumor-Specific Immunity for Cancer Immunotherapy

    Impaired tumor antigen HER2-specific recognition and immune response of senescent denderitic cells (DC) induced by γδ Treg cells were explored in vitro and in vivo in humanized mouse models.
    [Journal Of Immunotherapy of Cancer]

    Full Article

    Development of Adenoviral Vectors that Transduce Purkinje Cells and Other Cerebellar Cell-Types in the Cerebellum of a Humanized Mouse Model

    To overcome the current limitations of Adenoviral vectors (Ad) to treat central nervous system disorders, scientists created chimeric 1st generation Ad vectors that utilize the human CD46 receptor.
    [Molecular Therapy-Methods & Clinical Development]

    AbstractGraphical Abstract

    Mitochondrial DNA as a Target for Analyzing the Biodistribution of Cell Therapy Products

    Human adipose-derived stem cells, used as cell therapy products, were injected into the tail vein of athymic NCr-nu/nu mice and detected, seven days after administration, in their lungs at an average concentration of 2.22 ± 0.69 pg/μg mouse DNA, whereas Alu was not detected.
    [Scientific Reports]

    Full Article
    Meet the family of popular STEMCELL products. Click to explore.
    REVIEWS

    The Dual Role of Mesenchymal Stem Cells in Apoptosis Regulation

    MSCs transplantation therapy is widely used in the fields of tissue regeneration and repair, and treatment of inflammatory diseases. The authors summarize the current evidence on the regulation of apoptosis by MSCs.
    [Cell Death & Disease]

    Full Article
    INDUSTRY AND POLICY NEWS

    Cell Therapy Now Set to Reach more Patients with Expanded FDA Nod for Two Multiple Myeloma Drugs

    The CAR T-therapies Abecma and Carvykti may now be used in earlier lines of treatment for multiple myeloma. The expanded FDA approvals make these cell therapies more accessible to more patients, broadening the market for both products.
    [MedCity News]

    Press Release
    FEATURED EVENT

    ECCMID 2024

    April 27 – 30, 2024
    Barcelona, Spain

    > See All Events

    JOB OPPORTUNITIES

    PhD Scholarship – Regulatory T Cell Therapy for Inflammatory Bowel Disease

    Monash University – Melbourne, Victoria, Australia

    Associate Director – Stravitz-Sanyal Institute for Liver Disease

    Virginia Commonwealth University – Richmond, Virginia, United States

    Research Associate – Bioprinting, Biomaterials and Tissue Engineering

    New York University Abu Dhabi – Abu Dhabi, United Arab Emirates

    Director – Cell Therapy Innovation

    Cellistic – Mont-Saint-Guibert, Belgium

    Laboratory Scientist – Cell Therapy Research

    University of Colorado – Aurora, Colorado, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2